Literature DB >> 35476015

Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies.

Mazdak M Bradberry1,2, Natalie Gukasyan3,4, Charles L Raison5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35476015     DOI： 10.1001/jamapsychiatry.2022.0665

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN： 2168-622X            Impact factor:   25.911


× No keyword cloud information.
  2 in total

1.  Brain Wellness "Spas"-Anticipating the Off-label Promotion of Psychedelics.

Authors:  Anna Wexler; Dominic Sisti
Journal:  JAMA Psychiatry       Date:  2022-08-01       Impact factor: 25.911

Review 2.  Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.

Authors:  Sean J Belouin; Lynnette A Averill; Jack E Henningfield; Stephen N Xenakis; Ingrid Donato; Charles S Grob; Ann Berger; Veronica Magar; Alicia L Danforth; Brian T Anderson
Journal:  Neuropharmacology       Date:  2022-08-13       Impact factor: 5.273
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.